Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07730281
PHASE2

PRA-216 COPD Safety and Biomarker Study

Sponsor: Prana Therapies Inc

View on ClinicalTrials.gov

Summary

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).

Official title: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-08-25

Completion Date

2027-09-01

Last Updated

2026-10-28

Healthy Volunteers

No

Interventions

DRUG

PRA-216

biologic

DRUG

Placebo

matching placebo for PRA-216

Locations (5)

Emeritus Research Sydney

Botany, New South Wales, Australia

Campbelltown Hospital

Campbelltown, New South Wales, Australia

University of the Sunshine Coast

Birtinya, Queensland, Australia

Griffith University

Southport, Queensland, Australia

Emeritus Research Camberwell

Camberwell, Victoria, Australia